Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $4.60

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus rating of “Moderate Buy” by the six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $4.60.

Several equities analysts have issued reports on ALXO shares. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded shares of ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th.

ALX Oncology Stock Performance

ALXO stock opened at $1.97 on Friday. The stock has a 50-day moving average price of $1.92 and a 200-day moving average price of $1.96. ALX Oncology has a 1-year low of $0.66 and a 1-year high of $2.66. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm has a market cap of $272.41 million, a PE ratio of -1.74 and a beta of 0.42.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, equities research analysts expect that ALX Oncology will post -0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. venBio Partners LLC increased its stake in ALX Oncology by 32.8% in the first quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock valued at $25,834,000 after purchasing an additional 3,184,713 shares in the last quarter. Redmile Group LLC boosted its position in shares of ALX Oncology by 143.9% during the 1st quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after purchasing an additional 4,699,470 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of ALX Oncology in the 2nd quarter valued at about $15,317,000. Vivo Capital LLC acquired a new stake in shares of ALX Oncology in the 1st quarter valued at about $6,385,000. Finally, 5AM Venture Management LLC bought a new stake in ALX Oncology in the 2nd quarter valued at about $6,328,663,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.